News

Olaparib benefit maintained long term


 

AT THE 2016 ASCO ANNUAL MEETING

References

No new safety signals were observed with the longer follow-up, and the frequency of common adverse events, including nausea, fatigue, vomiting, and anemia was consistent with that seen in the overall population, with most adverse events initially reported during the first 2 years, he said.

The greatest benefits, in terms of overall survival and time to first and second subsequent treatment, were seen in patients with BRCA mutation, he concluded.

This study was sponsored by AstraZeneca. Dr. Ledermann reported that he has participated in advisory boards and lecture symposia and received institutional and personal fees from AstraZeneca, personal fees from Roche and Pfizer, and institutional fees from Clovis Oncology and Merck.

sworcester@frontlinemedcom.com

Pages

Recommended Reading

Management of adnexal masses in pregnancy
MDedge Hematology and Oncology
Novel combination delays progression of recurrent gynecologic tumors
MDedge Hematology and Oncology
ASCO issues clinical practice guidelines for invasive cervical cancer
MDedge Hematology and Oncology
Few locally advanced cervical cancer patients get guideline-directed therapies
MDedge Hematology and Oncology
VIDEO: IP chemo slows ovarian cancer progression
MDedge Hematology and Oncology
VIDEO: Dr. Maurie Markman says time to challenge established paradigms in cancer research
MDedge Hematology and Oncology
Gyn. oncologists are in demand for robotic hysterectomy
MDedge Hematology and Oncology
Lupus may confer higher risk for cervical cancer
MDedge Hematology and Oncology
Ethnic groups differ in BRCA risk management
MDedge Hematology and Oncology
Childhood cancer survivors face several long-term risks
MDedge Hematology and Oncology